Effectiveness Or Bust: Without Benefit, No Case For Keeping Makena On The Market, CDER Says

FDA Center for Drug Evaluation and Research officials say accelerated approval of Covis’ preterm birth prevention drug should be withdrawn because substantial evidence of effectiveness no longer exists – separate from any concerns about study feasibility, off-label use or compounding.